Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT
In Partnership With:
Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.
Sanjeet Singh Dadwal, MD, professor, chief, Division of Infectious Diseases, Department of Medicine, City of Hope, discusses the investigation of posoleucel (ALVR105; formerly Viralym-M) as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant (HCT).
At the 2022 ASH Annual Meeting, investigators presented data from a phase 2 trial (NCT05305040) evaluating clinical outcomes of posoleucel, a partially HLA-matched, off-the-shelf, multivirus-specific T cell investigational product for the prevention of clinically significant infections after allogeneic HCT.
Key findings from the study showed that the treatment was safe and well tolerated, Dadwal says. A main concern for patients following allogeneic HCT is the risk of graft-vs-host disease (GVHD). However, 19% of patients experienced grade II to IV acute GVHD, which aligned with previously reported historical rates for this patient population, Dadwal explains.
Serious adverse effects including skin GVHD, lung GVHD, and hypersensitivity. Notably, the patient who had experienced hypersensitivity was able to continue the treatment dosing; overall, 7 doses of posoleucel were well tolerated, Dadwal concludes.
